Literature DB >> 31980491

Familial pulmonary arterial hypertension by KDR heterozygous loss of function.

Mélanie Eyries1,2,3, David Montani4,5,6,3, Barbara Girerd4,5, Nicolas Favrolt7, Marianne Riou8, Laurence Faivre9, Grégoire Manaud6, Frédéric Perros6, Stefan Gräf10,11,12, Nicholas W Morrell10,13, Marc Humbert4,5,6, Florent Soubrier14,2.   

Abstract

Beyond the major gene BMPR2, several new genes predisposing to PAH have been identified during the last decade. Recently, preliminary evidence of the involvement of the KDR gene was found in a large genetic association study.We prospectively analysed the KDR gene by targeted panel sequencing in a series of 311 PAH patients referred to a clinical molecular laboratory for genetic diagnosis of PAH.Two index cases with severe PAH from two different families were found to carry a loss-of-function mutation in the KDR gene. These two index cases were clinically characterised by low diffusing capacity for carbon monoxide adjusted for haemoglobin (D LCOc) and interstitial lung disease. In one family, segregation analysis revealed that variant carriers are either presenting with PAH associated with low D LCOc, or have only decreased D LCOc, whereas non-carrier relatives have normal D LCOc. In the second family, a single affected carrier was alive. His carrier mother was unaffected with normal D LCOc.We provided genetic evidence for considering KDR as a newly identified PAH-causing gene by describing the segregation of KDR mutations with PAH in two families. In our study, KDR mutations are associated with a particular form of PAH characterised by low D LCOc and radiological evidence of parenchymal lung disease including interstitial lung disease and emphysema.
Copyright ©ERS 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31980491     DOI: 10.1183/13993003.02165-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

Review 1.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

Review 2.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4.

Authors:  Ignacio Hernandez-Gonzalez; Jair Tenorio; Julian Palomino-Doza; Amaya Martinez Meñaca; Rafael Morales Ruiz; Mauro Lago-Docampo; María Valverde Gomez; Javier Gomez Roman; Ana Belén Enguita Valls; Carmen Perez-Olivares; Diana Valverde; Joan Gil Carbonell; Elvira Garrido-Lestache Rodríguez-Monte; Maria Jesus Del Cerro; Pablo Lapunzina; Pilar Escribano-Subias
Journal:  PLoS One       Date:  2020-04-29       Impact factor: 3.240

Review 4.  Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.

Authors:  Hélène Le Ribeuz; Véronique Capuano; Barbara Girerd; Marc Humbert; David Montani; Fabrice Antigny
Journal:  Biomolecules       Date:  2020-09-01

5.  Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Daniel Greene; Na Zhu; Karyn Megy; Marcella Cogliano; Smitha Rajaram; Divya Pandya; Tobias Tilly; Katie A Lutz; Carrie C L Welch; Michael W Pauciulo; Laura Southgate; Jennifer M Martin; Carmen M Treacy; Christopher J Penkett; Jonathan C Stephens; Harm J Bogaard; Colin Church; Gerry Coghlan; Anna W Coleman; Robin Condliffe; Christina A Eichstaedt; Mélanie Eyries; Henning Gall; Stefano Ghio; Barbara Girerd; Ekkehard Grünig; Simon Holden; Luke Howard; Marc Humbert; David G Kiely; Gabor Kovacs; Jim Lordan; Rajiv D Machado; Robert V Mackenzie Ross; Colm McCabe; Shahin Moledina; David Montani; Horst Olschewski; Joanna Pepke-Zaba; Laura Price; Christopher J Rhodes; Werner Seeger; Florent Soubrier; Jay Suntharalingam; Mark R Toshner; Anton Vonk Noordegraaf; John Wharton; James M Wild; Stephen John Wort; Allan Lawrie; Martin R Wilkins; Richard C Trembath; Yufeng Shen; Wendy K Chung; Andrew J Swift; William C Nichols; Nicholas W Morrell; Stefan Gräf
Journal:  Circ Genom Precis Med       Date:  2020-12-15

Review 6.  Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension.

Authors:  Emmanuel Eroume-A Egom; Roger Moyou-Somo; Jean Louis Essame Oyono; Rene Kamgang
Journal:  Appl Clin Genet       Date:  2021-03-11

7.  Clinical Genetic Risk Variants Inform a Functional Protein Interaction Network for Tetralogy of Fallot.

Authors:  Miriam S Reuter; Rajiv R Chaturvedi; Rebekah K Jobling; Giovanna Pellecchia; Omar Hamdan; Wilson W L Sung; Thomas Nalpathamkalam; Pratyusha Attaluri; Candice K Silversides; Rachel M Wald; Christian R Marshall; Simon G Williams; Bernard D Keavney; Bhooma Thiruvahindrapuram; Stephen W Scherer; Anne S Bassett
Journal:  Circ Genom Precis Med       Date:  2021-07-30

8.  Endothelial HIF-2α as a Key Endogenous Mediator Preventing Emphysema.

Authors:  Shravani Pasupneti; Wen Tian; Allen B Tu; Petra Dahms; Eric Granucci; Aneta Gandjeva; Menglan Xiang; Eugene C Butcher; Gregg L Semenza; Rubin M Tuder; Xinguo Jiang; Mark R Nicolls
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 30.528

Review 9.  The role of genomics and genetics in pulmonary arterial hypertension.

Authors:  Emilia M Swietlik; Stefan Gräf; Nicholas W Morrell
Journal:  Glob Cardiol Sci Pract       Date:  2020-04-30

10.  Rare variants in KDR, encoding VEGF Receptor 2, are associated with tetralogy of Fallot.

Authors:  Doris Škorić-Milosavljević; Najim Lahrouchi; Fernanda M Bosada; Alex V Postma; Connie R Bezzina; Gregor Dombrowsky; Simon G Williams; Robert Lesurf; Fleur V Y Tjong; Roddy Walsh; Ihssane El Bouchikhi; Jeroen Breckpot; Enrique Audain; Aho Ilgun; Leander Beekman; Ilham Ratbi; Alanna Strong; Maximilian Muenke; Solveig Heide; Alison M Muir; Mariam Hababa; Laura Cross; Dihong Zhou; Tomi Pastinen; Elaine Zackai; Samir Atmani; Karim Ouldim; Najlae Adadi; Katharina Steindl; Anita Rauch; David Brook; Anna Wilsdon; Irene Kuipers; Nico A Blom; Barbara J Mulder; Heather C Mefford; Boris Keren; Pascal Joset; Paul Kruszka; Isabelle Thiffault; Sarah E Sheppard; Amy Roberts; Elisabeth M Lodder; Bernard D Keavney; Sally-Ann B Clur; Seema Mital; Marc-Philip Hitz; Vincent M Christoffels
Journal:  Genet Med       Date:  2021-06-10       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.